Article
BioCryst takes on Takeda, CSL with FDA approval for Orladeyo, the first pill to prevent HAE attacks
Rating:
0.0
Views:
119
Likes:
1
Library:
1
Ready to take on established competition from Takeda and CSL Behring, BioCryst Pharmaceuticals has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value